{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Administer SF-36, EQ-5D, FACIT-Fatigue, and WPS-RA (see Section 7.1.10).', 'Perform joint counts (Independent Joint Assessment) (see Section 7.1.2).', '- Joint assessor will be independent to the rest of the study team. An independent joint', 'assessor, blinded to other study assessments as well as the dosing regimen, will be', 'identified at each study site to perform the swollen joint count (SJC) and tender joint', 'count (TJC). To ensure consistent joint evaluation throughout the study, individual', 'subjects should be evaluated by the same joint assessor for all study visits whenever', 'possible.', 'Assess AEs/SAEs.', 'Assess injection site reactions that have occurred since the previous injection (see', 'Section 7.4.3.5).', 'Administer Physician Global Assessment (VAS) (see Section 7.1.5).', 'Record details of contraceptive history/status.', 'Record concomitant medications and concomitant non-drug therapies.', 'Administer TB risk questionnaire (see Section 7.4.9).', 'Record height and weight (see Section 7.4.7.3).', 'Record vital signs (see Section 7.4.7.2).', '- BP and heart rate also need to be reassessed 1 and 2 hours postdose.', 'Perform complete physical examination (see Section 7.4.7.1).', 'Perform CV risk assessment (see Section 7.4.7.4).', 'Perform 12-lead electrocardiogram (ECG) (see Section 7.4.7.4).', 'Perform chest X-ray (see Section 7.4.7.6).', '- Chest X-ray need not be conducted if performed and evaluated within 8 weeks prior', 'to Visit 1 (OLE Baseline/Week 24), and if the films or images are available and', \"included in the subject's source documents.\", 'Collect samples for international normalized ratio (INR), activated partial', 'thromboplastin time (aPTT), and fibrinogen (see Section 7.4.6.1).', 'Measure ESR (see Section 7.4.6.1).', 'Amendment 2: 06 March 2019', '59', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Collect sample to measure CRP level (see Section 7.4.6.1).', 'Collect samples for lipid panel and CV risk panel (see Section 7.4.6.1).', 'Collect samples for chemistry panel, hematology assessments, antinuclear antibodies', '(ANA), and double-stranded DNA (dsDNA) antibodies (see Section 7.4.6.1).', 'Collect PK sample prior to the first dose of study treatment (see Section 7.2).', 'Collect sample for analysis of ADAs (see Section 7.3).', 'Perform urine pregnancy test for females of childbearing potential only.', 'Perform urinalysis (see Section 7.4.6.1).', 'Allocate study treatment through the IWRS.', 'Distribute Subject Diary and train subjects to properly complete the Subject Diary (see', 'Section 5.5).', 'Perform training for study treatment preparation, storage, and administration (see', 'Section 6.8).', 'Administer study treatment.', '-', 'Study treatment will be administered by the subject (or caregiver, if applicable) at this', 'visit, and the Investigator must observe this administration to ensure that proper', 'procedures are followed', '- Subcutaneous injections may be rotated among the thighs and abdomen.', '- All subjects will remain at the study site for at least 2 hours after the injection to be', 'assessed for onset of any systemic injection reactions.', '5.4.1.2', 'Visit 2 (Week 26)', 'The following assessments will be performed at Visit 2 (Week 26):', 'Assess AEs/SAEs and injection site reactions that have occurred since the previous', 'visit.', 'Record details of contraceptive history/status.', 'Record concomitant medications and concomitant non-drug therapies.', 'Record weight.', 'Amendment 2: 06 March 2019', '60', 'Confidential']\n\n###\n\n", "completion": "END"}